Clinical Trial Update: A Randomized Study to Assess the Safety of GRF6019 Infusions in Subjects With Mild to Moderate Alzheimer's Disease [Phase 2]

View source ↗

Summary

Phase 2 randomized study completed evaluating the safety of GRF6019 infusions in mild to moderate Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• GRF6019

Snippet

Sponsor: Alkahest, Inc. | Conditions: Alzheimer Disease, Mild to Moderate Alzheimer Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-11-05